EGFR and non-small cell lung carcinoma: Combination therapy of ALK-TKIs and angiogenesis inhibitors may become an important treatment regimen, as combination therapy of EGFR-TKIs and angiogenesis inhibitors has shown efficacy for a part of EGFR-mutant NSCLC patients.